Sign in to view content

Dry AMD Symposium 2

Video
Published 2020

Related

GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
AMD Take Home Panel
Annual Meeting Talks
2020
Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2020

Category: AMD-Non-Neovascular

See more

Annual Meeting Talks